Donbgamecock wrote: LidLid wrote: APHA is moving sideway and waiting a catalyst to jump up, let's see what is the catalyst.
Theres no doubt that sp has been moving sideways. There are numerous catalysts that can get the sp moving up again. A few are:
* HC approval on PIV
* Completion of DD and PV
* Complete the closure of the Germany CC Pharma deal
* Strong quarterly numbers
Take note that I didn’t mention any partnering or JV deal. Let’s just focus on things we really know about. This board has seen enough dillusional predictions and completely idiotic statements about all these supposed deals.
The 1st three points will set the pace for 2019 revenue streams. Early HC approval is vital to a good 2019.
There are certain points Ill be looking for in the qrtly report.
1. Strong revenue to demonstrate QOQ growth.
2. Recovery from last reports eroding all in costs per gram
3. Completion schedule and production predictions stay in line with last reports statements. Last report informed investors of lower yields and 3-6 month delays in expansion efforts
4. Revenue income from LATM acquisions
5. I fully expect bad news in many of the stock holdings the company invested in.
6. Last report had unexpected losses and increases in costs. Expect acquisition, legal, G&A costs to be on the rise
7. Increase in PPS